ECOG 6202 A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2014
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2009 New source identified and integrated New Jersey Cancer Trial Connect.
- 30 Jun 2009 Additional lead trial investigator Kasimis BS identified as reported by New Jersey Cancer Trial Connect